Novel Cyclic Hexapeptides from Marine-Derived Fungus, Aspergillus sclerotiorum PT06-1

2009 ◽  
Vol 11 (22) ◽  
pp. 5262-5265 ◽  
Author(s):  
Jinkai Zheng ◽  
Huajie Zhu ◽  
Kui Hong ◽  
Yi Wang ◽  
Peipei Liu ◽  
...  
Marine Drugs ◽  
2021 ◽  
Vol 19 (12) ◽  
pp. 701
Author(s):  
Jieyi Long ◽  
Yaqi Chen ◽  
Weihao Chen ◽  
Junfeng Wang ◽  
Xuefeng Zhou ◽  
...  

Three novel cyclic hexapeptides, sclerotides C–E (1–3), and a new lipodepsipeptide, scopularide I (4), together with a known cyclic hexapeptide sclerotide A (5), were isolated from fermented rice cultures of a soft coral-derived fungus: Aspergillus sclerotiorum SCSIO 41031. The structures of the new peptides were determined by 1D and 2D NMR spectroscopic analysis, Marfey’s method, ESIMS/MS analysis, and single crystal X-ray diffraction analysis. Scopularide I (4) exhibited acetylcholinesterase inhibitory activity with an IC50 value of 15.6 μM, and weak cytotoxicity against the human nasopharyngeal carcinoma cell line HONE-EBV with IC50 values of 10.1 μM.


Toxins ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 522
Author(s):  
Patrick Romano Monteiro ◽  
Samuel Cavalcante do Amaral ◽  
Andrei Santos Siqueira ◽  
Luciana Pereira Xavier ◽  
Agenor Valadares Santos

Cyanobacteria are microorganisms with photosynthetic mechanisms capable of colonizing several distinct environments worldwide. They can produce a vast spectrum of bioactive compounds with different properties, resulting in an improved adaptative capacity. Their richness in secondary metabolites is related to their unique and diverse metabolic apparatus, such as Non-Ribosomal Peptide Synthetases (NRPSs). One important class of peptides produced by the non-ribosomal pathway is anabaenopeptins. These cyclic hexapeptides demonstrated inhibitory activity towards phosphatases and proteases, which could be related to their toxicity and adaptiveness against zooplankters and crustaceans. Thus, this review aims to identify key features related to anabaenopeptins, including the diversity of their structure, occurrence, the biosynthetic steps for their production, ecological roles, and biotechnological applications.


2017 ◽  
Vol 58 (27) ◽  
pp. 2675-2680 ◽  
Author(s):  
Lissa S. Tsutsumi ◽  
Ghee T. Tan ◽  
Dianqing Sun

ChemInform ◽  
1988 ◽  
Vol 19 (1) ◽  
Author(s):  
T. INABA ◽  
I. UMEZAWA ◽  
M. YUASA ◽  
T. INOUE ◽  
S. MIHASHI ◽  
...  

Biochemistry ◽  
1971 ◽  
Vol 10 (8) ◽  
pp. 1330-1335 ◽  
Author(s):  
C. Allen Bush ◽  
Stanley M. Ziegler

1996 ◽  
Vol 59 (6) ◽  
pp. 570-575 ◽  
Author(s):  
David E. Williams ◽  
Marcia Craig ◽  
Charles F. B. Holmes ◽  
Raymond J. Andersen
Keyword(s):  

1967 ◽  
Vol 1 (4) ◽  
pp. 219-230 ◽  
Author(s):  
Naftale Katz ◽  
J. Pellegrino

A partir do Miracil D, um derivado hidroximetílico (Hycanthone) pode ser obtido através da atividade biológica do Aspergillus sclerotiorum. Êste derivado mostrou-se muito ativo quando administrado a camundongos, hamsters e macacos Cebus experimentalmente infectados com Schistosoma mansoni. Ensaios clínicos com o Hycanthone foram feitos em 52 pacientes com esquistossomose mansoni ativa. A droga foi administrada, nas doses de 2 e 3 mg/kg/ dia, junto com um anti-ácido, duas vêzes ao dia, durante 5 dias consecutivos. Com exceção de 2 casos, todos os pacientes completaram o tratamento. Náusea e/ou vômito, anorexia, tonturas e cefaléia foram os efeitos colaterais mais comuns. Atividade terapêutica foi avaliada através de repetidos exames de fezes (4 a 6) e uma biópsia retal realizada a partir do 4.° mês após o tratamento. As percentagens de cura foram de 83,3 e 80,0% com o esquema de 2 e 3 mg/kg, respectivamente. Os dados laboratoriais e clínicos sôbre a atividade esquistossomicida do Hycanthone até agora obtidos mostram a necessidade de novos ensaios com êste promissor medicamento.


1973 ◽  
Vol 4 (45) ◽  
pp. no-no
Author(s):  
KENNETH D. KOPPLE ◽  
ANITA GO ◽  
THOMAS J. SCHAMPER ◽  
CRAIG S. WILCOX

Sign in / Sign up

Export Citation Format

Share Document